SK Biopharm and SK Bioscience Make 'First' Appearance at BIO USA

SK Biopharm and SK Bioscience announced on the 4th that they participated in the 2024 BIO International Convention (BIO USA), the world's largest bio-industry exhibition held from the 3rd to the 6th (local time) in San Diego, USA. BIO USA is an international event organized by the Biotechnology Innovation Organization (BIO) in the United States, attended by more than 1,500 pharmaceutical and bio companies and over 20,000 industry professionals worldwide.

The joint promotional booth of SK Bioscience and SK Biopharm set up at the 2024 BIO International Convention (BIO USA) held in San Diego, California, USA.
[Photo by SK Bioscience·SK Biopharm]

SK Biopharm and SK Bioscience jointly set up a promotional booth at this event to pursue partnering opportunities with global companies. For both companies, this is the first time operating a promotional booth at an international-scale bio exhibition. Accordingly, they plan to showcase SK Group's bio capabilities through this event to seek opportunities for expanding their global business.

On the first day of the event, the 3rd, a large number of visitors, including representatives from global companies, visited the promotional booth, confirming the high domestic and international interest in SK's bio business. Then, on the 4th and 5th, presentations were prepared to be conducted directly by executives from local subsidiaries in the United States. On the 4th, an executive in charge of global clinical development at SK Life Science USA shared the 'success story from clinical trials to direct sales in the U.S.', and on the 5th, executives from SK Life Science Labs, acquired last year, introduced the 'new drug development strategy through MOPED, an innovative platform for discovering molecular glue (MG) related to targeted protein degradation (TPD) technology.'

SK Bioscience expressed its determination to leap forward as a fully integrated vaccine and bio company covering research and development (R&D), production, and contract development and manufacturing organization (CDMO) based on global partnerships. During the event, they introduced their major self-developed vaccines and pipelines, as well as their global expansion strategy based on state-of-the-art production facilities and R&D capabilities. In addition, they plan to identify the latest industry trends and explore new business opportunities through individual meetings with major global companies and institutions.

Lee Dong-hoon, CEO of SK Biopharm, said, “We expect to promote SK’s bio business and further expand partnerships through this event,” adding, “As a domestic bio company that has successfully entered the U.S. market with self-developed innovative new drugs, we will also consider our responsibilities and roles.” An Jae-yong, CEO of SK Bioscience, said, “Through BIO USA, we expect to strengthen relationships with companies and institutions with which we have formed partnerships so far and increase opportunities for new partnership agreements,” adding, “We will respond to the heightened interest in SK’s bio business since the COVID-19 pandemic and create an opportunity for full-scale entry into the global market.”